Damon A. Hofman

Damon A. Hofman

Auto-generated profile, based on publicly available information

Damon A. Hofman

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584, CS, Utrecht, The Netherlands; Oncode Institute, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in Trends in Genetics
Verified
Journal Article
Open access
DHDamon A. Hofman
Damon A. Hofman
JPJohn R. Prensner
John R. Prensner
SHSebastiaan van Heesch
Sebastiaan van Heesch
Cancer continues to be a major global health challenge, accounting for 10 million deaths annually worldwide. Since the inception of genome-wide cancer sequencing studies 20 years ago, a core set of ~700 oncogenes and tumor suppressor genes has become the basis for cancer research. However, this research has been based largely on an understanding that the human genome encodes ~19 500 protein-coding genes. Complementing this genomic landscape, recent advances have described numerous microproteins which are now poised to redefine our understanding of oncogenic processes and open new avenues for therapeutic intervention. This review explores the emerging evidence for microprotein involvement in cancer mechanisms and discusses potential therapeutic applications, with an emphasis on highlighting recent advances in the field.

15 December 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ACAnnelisa Cornel
Annelisa Cornel
EDEster Dunnebach
Ester Dunnebach
DHDamon A Hofman
Damon A Hofman
SDSanjukta Das
Sanjukta Das
SSSatyaki Sengupta
Satyaki Sengupta
SNStefan Nierkens
Stefan Nierkens
Background Immunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full potential due to inadequate (adaptive) immune engagement caused by the extensive immunomodulatory capacity of HR-NBL. We aimed to tackle one of the most notable immunomodulatory processes in neuroblastoma (NBL), absence of major histocompatibility complex class I (MHC-I) surface expression, a process greatly limiting cytotoxic T cell engagement. We and others have previously shown that MHC-I expression can be induced by cytokine-driven immune modulation. Here, we aimed to identify tolerable pharmacological repurposing strategies to upregulate MHC-I expression and therewith enhance T cell immunogenicity in NBL. Methods Drug repurposing libraries were screened to identify compounds enhancing MHC-I surface expression in NBL cells using high-throughput flow cytometry analyses optimized for adherent cells. The effect of positive hits was confirmed in a panel of NBL cell lines and patient-derived organoids. Compound-treated NBL cell lines and organoids were cocultured with preferentially expressed antigen of melanoma (PRAME)-reactive tumor-specific T cells and healthy-donor natural killer (NK) cells to determine the in vitro effect on T cell and NK cell cytotoxicity. Additional immunomodulatory effects of histone deacetylase inhibitors (HDACi) were identified by transcriptome and translatome analysis of treated organoids. Results Drug library screening revealed MHC-I upregulation by inhibitor of apoptosis inhibitor (IAPi)- and HDACi drug classes. The effect of IAPi was limited due to repression of nuclear factor kappa B (NFκB) pathway activity in NBL, while the MHC-I-modulating effect of HDACi was widely translatable to a panel of NBL cell lines and patient-derived organoids. Pretreatment of NBL cells with the HDACi entinostat enhanced the cytotoxic capacity of tumor-specific T cells against NBL in vitro, which coincided with increased expression of additional players regulating T cell cytotoxicity (eg, TAP1/2 and immunoproteasome subunits). Moreover, MICA and MICB, important in NK cell cytotoxicity, were also increased by entinostat exposure. Intriguingly, this increase in immunogenicity was accompanied by a shift toward a more mesenchymal NBL cell lineage. Conclusions This study indicates the potential of combining (immuno)therapy with HDACi to enhance both T cell-driven and NKcell-driven immune responses in patients with HR-NBL.

25 November 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MPMireia Palomar-Siles
Mireia Palomar-Siles
AHAngelos Heldin
Angelos Heldin
MZMeiqiongzi Zhang
Meiqiongzi Zhang
CSCharlotte Strandgren
Charlotte Strandgren
VYViktor Yurevych
Viktor Yurevych
KWKlas G. Wiman
Klas G. Wiman
TP53 nonsense mutations in cancer produce truncated inactive p53 protein. We show that 5-FU metabolite 5-Fluorouridine (FUr) induces full-length p53 in human tumor cells carrying R213X nonsense mutant TP53. Ribosome profiling visualized translational readthrough at the R213X premature stop codon and demonstrated that FUr-induced readthrough is less permissive for canonical stop codon readthrough compared to aminoglycoside G418. FUr is incorporated into mRNA and can potentially base-pair with guanine, allowing insertion of Arg tRNA at the TP53 R213X UGA premature stop codon and translation of full-length wild-type p53. We confirmed that full-length p53 rescued by FUr triggers tumor cell death by apoptosis. FUr also restored full-length p53 in TP53 R213X mutant human tumor xenografts in vivo. Thus, we demonstrate a novel strategy for therapeutic rescue of nonsense mutant TP53 and suggest that FUr should be explored for treatment of patients with TP53 nonsense mutant tumors.

4 April 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate the whole-genome and long-read transcript sequencing of cancers to identify the collection of neo-open reading frame peptides (NOP) expressed in tumors. We termed this collection of NOPs the tumor framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe a class of hidden NOPs that derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of noncoding regions of the genome downstream of a rearrangement breakpoint, i.e., where no gene annotation or evidence for transcription exists. The entire collection of NOPs represents a vast number of possible neoantigens particularly in tumors with many structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T cells specific for hidden NOPs in peripheral blood from a patient with lung cancer. This work highlights NOPs as a major source of possible neoantigens for personalized cancer immunotherapy and provides a rationale for analyzing the complete cancer genome and transcriptome as a basis for the detection of NOPs.

6 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DHDamon A. Hofman
Damon A. Hofman
JRJorge Ruiz-Orera
Jorge Ruiz-Orera
IYIan Yannuzzi
Ian Yannuzzi
RMRakesh Murugesan
Rakesh Murugesan
ABAdam Brown
Adam Brown
JPJohn R. Prensner
John R. Prensner
A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation. Currently, it is unknown whether medulloblastoma dysregulates the translation of putatively oncogenic non-canonical open reading frames. To address this question, we performed ribosome profiling of 32 medulloblastoma tissues and cell lines and observed widespread non-canonical ORF translation. We then developed a step-wise approach to employ multiple CRISPR-Cas9 screens to elucidate functional non-canonical ORFs implicated in medulloblastoma cell survival. We determined that multiple lncRNA-ORFs and upstream open reading frames (uORFs) exhibited selective functionality independent of the main coding sequence. One of these, ASNSD1-uORF or ASDURF, was upregulated, associated with the MYC family oncogenes, and was required for medulloblastoma cell survival through engagement with the prefoldin-like chaperone complex. Our findings underscore the fundamental importance of non-canonical ORF translation in medulloblastoma and provide a rationale to include these ORFs in future cancer genomics studies seeking to define new cancer targets. Highlights Ribo-seq reveals widespread translation of non-canonical ORFs in medulloblastoma High-resolution CRISPR tiling reveals uORF functions in medulloblastoma ASNSD1-uORF controls downstream pathways with the prefoldin-like complex ASNSD1-uORF is necessary for medulloblastoma cell survival

17 June 2026
Verified
Other
Open access
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Figure S3: Identifying FRM0469-dextramer-positive CD8+ T cells.